Xenotransplantation—the current status and prospects

Abstract Introduction There is a continuing worldwide shortage of organs from deceased human donors for transplantation into patients with end-stage organ failure. Genetically engineered pigs could resolve this problem, and could also provide tissues and cells for the treatment of conditions such as...

Full description

Saved in:
Bibliographic Details
Published in:British medical bulletin 2018-03, Vol.125 (1), p.5-14
Main Authors: Cooper, D K C, Gaston, R, Eckhoff, D, Ladowski, J, Yamamoto, T, Wang, L, Iwase, H, Hara, H, Tector, M, Tector, A J
Format: Article
Language:English
Subjects:
Animals
Animals, Genetically Modified
Editor's Choice
Graft Survival
Heterografts
Humans
Invited Review
Swine
Tissue and Organ Harvesting - methods
Transplantation, Heterologous - adverse effects
Transplantation, Heterologous - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction There is a continuing worldwide shortage of organs from deceased human donors for transplantation into patients with end-stage organ failure. Genetically engineered pigs could resolve this problem, and could also provide tissues and cells for the treatment of conditions such as diabetes, Parkinson’s disease and corneal blindness. Sources of data The current literature has been reviewed. Areas of agreement The pathobiologic barriers are now largely defined. Research progress has advanced through the increasing availability of genetically engineered pigs and novel immunosuppressive agents. Life-supporting pig kidneys and islets have functioned for months or years in nonhuman primates. Areas of controversy The potential risk of transfer of a pig infectious microorganism to the recipient continues to be debated. Growing points Increased attention is being paid to selection of patients for initial clinical trials. Areas timely for developing research Most of the advances required to justify a clinical trial have now been met.
ISSN:0007-1420
1471-8391
DOI:10.1093/bmb/ldx043